On August 7, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer, sold 2,280 shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), as reported in a recent SEC filing. Following this transaction, the insider now owns 23,259 shares of the company.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology company focused on developing and commercializing therapies to treat cystic fibrosis and other serious diseases. The company’s strategy includes continued investment in a robust pipeline of drugs, several of which are in various stages of clinical development.
Over the past year, Carmen Bozic has sold a total of 47,585 shares and purchased no shares of the company. This latest transaction is part of a broader trend seen at Vertex Pharmaceuticals Inc., where there were 68 insider sales and no insider purchases over the past year.
On the day of the last transaction, Vertex Pharmaceuticals Inc. shares were trading at $476.75, giving the company a market capitalization of approximately $120.27 billion. This valuation reflects a price-to-earnings ratio, a price-to-sales ratio, a price-to-book ratio and a price-to-free cash flow ratio that are in line with the competitive landscape of the industry.
According to GF Value, Vertex Pharmaceuticals Inc.’s intrinsic value is estimated at $377.06 per share, suggesting that the stock is slightly overvalued with a Price to GF Value ratio of 1.26.
The GF Score is calculated based on historical trading multiples, an adjustment factor from GuruFocus based on past company performance, and estimates of future business performance provided by Morningstar analysts.
The insider selling trend and current stock valuation provide important data points for investors monitoring Vertex Pharmaceuticals Inc. stock performance and insider activities.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
